نتایج جستجو برای: cisplatin toxicity

تعداد نتایج: 143067  

Journal: :The New England journal of medicine 2003
Arlene A Forastiere Helmuth Goepfert Moshe Maor Thomas F Pajak Randal Weber William Morrison Bonnie Glisson Andy Trotti John A Ridge Clifford Chao Glen Peters Ding-Jen Lee Andrea Leaf John Ensley Jay Cooper

BACKGROUND Induction chemotherapy with cisplatin plus fluorouracil followed by radiotherapy is the standard alternative to total laryngectomy for patients with locally advanced laryngeal cancer. The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown. METHODS We randomly assigned patients with locally advanced cancer of the larynx to one of three tr...

Journal: :physiology and pharmacology 0
mehdi nematbakhsh water & electrolytes research center, isfahan university of medical sciences, isfahan, iran fariba azarkish water & electrolytes research center, isfahan university of medical sciences, isfahan, iran ali-asghar poorshahnazari department of physiology, isfahan university of medical sciences, isfahan, iran

introduction: cisplatin (cp) therapy may disturb cardiovascular system control. the objective of this study was to find baroreflex sensitivity (brs) in cp-induced nephrotoxicity in rats. materials and methods: eighteen male and female wistar rats were randomly assigned to two groups treated with cp (2.5 mg/kg/day) and the vehicle, for five consecutive days, and then were subjected to surgical p...

Journal: :The Journal of thoracic and cardiovascular surgery 2006
D Lardinois F J Jung I Opitz K Rentsch C Latkoczy V Vuong Z Varga V Rousson D Günther S Bodis R Stahel W Weder

OBJECTIVE We sought to investigate whether intrapleural topical application of cisplatin with a surgical carrier has a prolonged local tissue level in comparison with cisplatin solution while reducing systemic toxicity. METHODS Forty immune-competent Fischer rats were inoculated with 10(6) mesothelioma cells. Ten days later, left pneumonectomy with tumor debulking was performed. Twenty animal...

2015
Niramol Savaraj Chunjing Wu Ying-Ying Li Medhi Wangpaichitr Min You John Bomalaski Wei He Macus Tien Kuo Lynn G. Feun

Loss of argininosuccinate synthetase (ASS) expression in melanoma makes these tumor cells vulnerable to arginine deprivation. Pegylated arginine deiminase (ADI-PEG20) which degrades arginine to citrulline and ammonia has been used clinically and partial responses and stable disease have been noted with minimal toxicity. In order to improve the therapeutic efficacy of ADI-PEG20, we have combined...

Journal: :Clinical science 2004
N I Weijl T J Elsendoorn R M W Moison E G W M Lentjes R Brand H M Berger S Osanto

Non-protein bound iron (NPBI) is able to catalyse oxidative reactions, causing damage to vital structures. Adverse effects induced by cisplatin seem, in part, to be mediated by free radicals. In the present study, we have measured plasma NPBI, various other iron parameters and antioxidants in 28 cancer patients undergoing cisplatin-based chemotherapy at various time points before and during che...

2012
Vijayakumar Narayanan Bibek Bista Samir Sharma

Introduction. External beam pelvic radiotherapy with cisplatin and brachytherapy is the standard of care for patients with advanced cervical malignancy. This study was aimed at evaluating the toxicity of a two-field radiotherapy with cisplatin and brachytherapy compared to a four-field box technique with paclitaxel and brachytherapy for stages IIB/IIIB cervical cancer. The differences in respon...

2015
Jing Yu Jing Xiao Yifan Yang Bangwei Cao Yang Liu.

The efficacy and toxicity of oxaliplatin-based versus carboplatin/cisplatin-based doublets in patients with previously untreated nonsmall cell lung cancer (NSCLC) have been compared.We searched published randomized controlled trials of oxaliplatin-based or carboplatin/cisplatin-based medications for NSCLC. A fixed effect model was used to analyze outcomes which were expressed as the hazard rati...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 1998
J Lokich N Anderson

BACKGROUND Introduced into clinical usage in 1992 as a platinum analogue with a distinctively different toxicity profile from cisplatin, carboplatin has become a commonly preferred agent over cisplatin. The comparative therapeutic efficacy of the two agents remains controversial however, prompting an analysis of the phase III trials in ovarian cancer and other tumors in which the two were compa...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2007
Dae Ho Lee Sang-We Kim Kyun-Seop Bae Jeong-Sook Hong Cheolwon Suh Yoon-Koo Kang Jung-Shin Lee

PURPOSE Belotecan (Camtobell, CKD602) is a novel camptothecin derivative. This study was designed to determine the maximum tolerated dose (MTD), toxicity profile, and dose-limiting toxicity of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer (SCLC). Furthermore, pharmacokinetics and preliminary antitumor activity agains...

Journal: :Journal of cancer research and therapeutics 2008
Jisha Joy Cherupally Krishnan Krishnan Nair

BACKGROUND Cisplatin is one of the most effective chemotherapeutics against a wide range of cancers including head, neck, ovarian and lung cancers. But its usefulness is limited by its toxicity to normal tissues, including cells of the kidney proximal tubule. The purpose of the present study is to investigate whether the hydro-alcoholic extract of Rubia cordifolia could decrease the intensity o...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید